Celldex Therapeutics, Inc. (NASDAQ:CLDX): Insiders Are Dumping, Should You?

Is Celldex Therapeutics, Inc. (NASDAQ:CLDX) ready to raly soon? Money managers are selling. The number of bullish hedge fund bets stayed the same which is a slightly negative development in our experience

To the average investor, there are dozens of gauges shareholders can use to monitor their holdings. A couple of the most useful are hedge fund and insider trading activity. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite fund managers can outclass the S&P 500 by a healthy amount (see just how much).

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Just as important, bullish insider trading activity is a second way to break down the marketplace. Obviously, there are lots of motivations for a corporate insider to sell shares of his or her company, but only one, very obvious reason why they would buy. Many empirical studies have demonstrated the market-beating potential of this tactic if you understand what to do (learn more here).

Now, we’re going to take a glance at the key action encompassing Celldex Therapeutics, Inc. (NASDAQ:CLDX).

How are hedge funds trading Celldex Therapeutics, Inc. (NASDAQ:CLDX)?

In preparation for this year, a total of 12 of the hedge funds we track were bullish in this stock, a change of 0% from one quarter earlier. With hedge funds’ positions undergoing their usual ebb and flow, there exists a select group of noteworthy hedge fund managers who were upping their holdings meaningfully.

According to our comprehensive database, Steven Cohen’s SAC Capital Advisors had the largest position in Celldex Therapeutics, Inc. (NASDAQ:CLDX), worth close to $18 million, comprising 0.1% of its total 13F portfolio. Sitting at the No. 2 spot is Arthur B Cohen and Joseph Healey of Healthcor Management LP, with a $14 million position; 0% of its 13F portfolio is allocated to the stock. Remaining hedgies that are bullish include Jean-Marie Eveillard’s First Eagle Investment Management, Donald Chiboucis’s Columbus Circle Investors and D. E. Shaw’s D E Shaw.

Judging by the fact that Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced declining sentiment from the smart money, we can see that there is a sect of money managers who were dropping their positions entirely at the end of the year. Intriguingly, Wayne Holman’s Ridgeback Capital Management dumped the biggest position of all the hedgies we monitor, comprising about $18 million in stock., and Mike Vranos of Ellington was right behind this move, as the fund dropped about $0 million worth. These transactions are important to note, as total hedge fund interest stayed the same (this is a bearish signal in our experience).

How have insiders been trading Celldex Therapeutics, Inc. (NASDAQ:CLDX)?

Insider buying is most useful when the company in focus has seen transactions within the past half-year. Over the latest 180-day time frame, Celldex Therapeutics, Inc. (NASDAQ:CLDX) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

With the results demonstrated by our time-tested strategies, everyday investors must always keep an eye on hedge fund and insider trading sentiment, and Celldex Therapeutics, Inc. (NASDAQ:CLDX) is an important part of this process.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!